Reviews Cleocin I.V.


No reviews yet.

Cleocin I.V. Drug Description
Cleocin Phosphate®
(clindamycin) Injection, USP and (clindamycin) Injection in 5% Dextrose
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PHOSPHATE and other antibacterial drugs, CLEOCIN PHOSPHATE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Sterile Solution is for Intramuscular and Intravenous Use
CLEOCIN PHOSPHATE in the ADD-Vantage™ Vial is For Intravenous Use
Only

WARNING
Clostridium difficile associated diarrhea (CDAD) has been reported with
use of nearly all antibacterial agents, including CLEOCIN PHOSPHATE and may
range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial
agents alters the normal flora of the colon leading to overgrowth of C. difficile.
Because CLEOCIN PHOSPHATE therapy has been associated with severe colitis which
may end fatally, it should be reserved for serious infections where less toxic
antimicrobial agents are inappropriate, as described in the INDICATIONS
section. It should not be used in patients with nonbacterial infections such
as most upper respiratory tract infections. C. difficile produces toxins
A and B which contribute to the development of CDAD. Hypertoxin producing strains
of C. difficile cause increased morbidity and mortality, as these infections
can be refractory to antimicrobial therapy and may require colectomy. CDAD must
be considered in all patients who present with diarrhea following antibiotic
use. Careful medical history is necessary since CDAD has been reported to occur
over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against
C. difficile may need to be discontinued. Appropriate fluid and electrolyte
management, protein supplementation, antibiotic treatment of C. difficile,
and surgical evaluation should be instituted as clinically indicated.

DRUG DESCRIPTION
CLEOCIN PHOSPHATE Sterile Solution in vials contains clindamycin phosphate, a water soluble ester of clindamycin and phosphoric acid. Each mL contains the equivalent of 150 mg clindamycin, 0.5 mg disodium edetate and 9.45 mg benzyl alcohol added as preservative in each mL. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.
The chemical name of clindamycin phosphate is L-threo-α-D-galacto-Octopyranoside,
methyl 7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]
amino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-.
The molecular formula is C18H34CIN208PS
and the molecular weight is 504.96.
The structural formula is represented below:








CLEOCIN PHOSPHATE in the ADD-Vantage Vial is intended for intravenous use
only after further dilution with appropriate volume of ADD-Vantage diluent base
solution.
CLEOCIN PHOSPHATE IV Solution in the Galaxy® plastic container for intravenous use is composed of clindamycin phosphate equivalent to 300, 600 and 900 mg of clindamycin premixed with 5% dextrose as a sterile solution. Disodium edetate has been added at a concentration of 0.04 mg/mL. The pH has been adjusted with sodium hydroxide and/or hydrochloric acid.
The plastic container is fabricated from a specially designed multilayer plastic, PL 2501. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period. The suitability of the plastic has been confirmed in tests in animals according to the USP biological tests for plastic containers, as well as by tissue culture toxicity studies.
Last reviewed on RxList: 4/3/2009




Cleocin I.V. Drug Description
Cleocin Phosphate®
(clindamycin) Injection, USP and (clindamycin) Injection in 5% Dextrose
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PHOSPHATE and other antibacterial drugs, CLEOCIN PHOSPHATE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Sterile Solution is for Intramuscular and Intravenous Use
CLEOCIN PHOSPHATE in the ADD-Vantage™ Vial is For Intravenous Use
Only

WARNING
Clostridium difficile associated diarrhea (CDAD) has been reported with
use of nearly all antibacterial agents, including CLEOCIN PHOSPHATE and may
range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial
agents alters the normal flora of the colon leading to overgrowth of C. difficile.
Because CLEOCIN PHOSPHATE therapy has been associated with severe colitis which
may end fatally, it should be reserved for serious infections where less toxic
antimicrobial agents are inappropriate, as described in the INDICATIONS
section. It should not be used in patients with nonbacterial infections such
as most upper respiratory tract infections. C. difficile produces toxins
A and B which contribute to the development of CDAD. Hypertoxin producing strains
of C. difficile cause increased morbidity and mortality, as these infections
can be refractory to antimicrobial therapy and may require colectomy. CDAD must
be considered in all patients who present with diarrhea following antibiotic
use. Careful medical history is necessary since CDAD has been reported to occur
over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against
C. difficile may need to be discontinued. Appropriate fluid and electrolyte
management, protein supplementation, antibiotic treatment of C. difficile,
and surgical evaluation should be instituted as clinically indicated.

DRUG DESCRIPTION
CLEOCIN PHOSPHATE Sterile Solution in vials contains clindamycin phosphate, a water soluble ester of clindamycin and phosphoric acid. Each mL contains the equivalent of 150 mg clindamycin, 0.5 mg disodium edetate and 9.45 mg benzyl alcohol added as preservative in each mL. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.
The chemical name of clindamycin phosphate is L-threo-α-D-galacto-Octopyranoside,
methyl 7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]
amino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-.
The molecular formula is C18H34CIN208PS
and the molecular weight is 504.96.
The structural formula is represented below:








CLEOCIN PHOSPHATE in the ADD-Vantage Vial is intended for intravenous use
only after further dilution with appropriate volume of ADD-Vantage diluent base
solution.
CLEOCIN PHOSPHATE IV Solution in the Galaxy® plastic container for intravenous use is composed of clindamycin phosphate equivalent to 300, 600 and 900 mg of clindamycin premixed with 5% dextrose as a sterile solution. Disodium edetate has been added at a concentration of 0.04 mg/mL. The pH has been adjusted with sodium hydroxide and/or hydrochloric acid.
The plastic container is fabricated from a specially designed multilayer plastic, PL 2501. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period. The suitability of the plastic has been confirmed in tests in animals according to the USP biological tests for plastic containers, as well as by tissue culture toxicity studies.
Last reviewed on RxList: 4/3/2009




Cleocin I.V. Drug Description
Cleocin Phosphate®
(clindamycin) Injection, USP and (clindamycin) Injection in 5% Dextrose
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PHOSPHATE and other antibacterial drugs, CLEOCIN PHOSPHATE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Sterile Solution is for Intramuscular and Intravenous Use
CLEOCIN PHOSPHATE in the ADD-Vantage™ Vial is For Intravenous Use
Only

WARNING
Clostridium difficile associated diarrhea (CDAD) has been reported with
use of nearly all antibacterial agents, including CLEOCIN PHOSPHATE and may
range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial
agents alters the normal flora of the colon leading to overgrowth of C. difficile.
Because CLEOCIN PHOSPHATE therapy has been associated with severe colitis which
may end fatally, it should be reserved for serious infections where less toxic
antimicrobial agents are inappropriate, as described in the INDICATIONS
section. It should not be used in patients with nonbacterial infections such
as most upper respiratory tract infections. C. difficile produces toxins
A and B which contribute to the development of CDAD. Hypertoxin producing strains
of C. difficile cause increased morbidity and mortality, as these infections
can be refractory to antimicrobial therapy and may require colectomy. CDAD must
be considered in all patients who present with diarrhea following antibiotic
use. Careful medical history is necessary since CDAD has been reported to occur
over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against
C. difficile may need to be discontinued. Appropriate fluid and electrolyte
management, protein supplementation, antibiotic treatment of C. difficile,
and surgical evaluation should be instituted as clinically indicated.

DRUG DESCRIPTION
CLEOCIN PHOSPHATE Sterile Solution in vials contains clindamycin phosphate, a water soluble ester of clindamycin and phosphoric acid. Each mL contains the equivalent of 150 mg clindamycin, 0.5 mg disodium edetate and 9.45 mg benzyl alcohol added as preservative in each mL. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.
The chemical name of clindamycin phosphate is L-threo-α-D-galacto-Octopyranoside,
methyl 7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]
amino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-.
The molecular formula is C18H34CIN208PS
and the molecular weight is 504.96.
The structural formula is represented below:








CLEOCIN PHOSPHATE in the ADD-Vantage Vial is intended for intravenous use
only after further dilution with appropriate volume of ADD-Vantage diluent base
solution.
CLEOCIN PHOSPHATE IV Solution in the Galaxy® plastic container for intravenous use is composed of clindamycin phosphate equivalent to 300, 600 and 900 mg of clindamycin premixed with 5% dextrose as a sterile solution. Disodium edetate has been added at a concentration of 0.04 mg/mL. The pH has been adjusted with sodium hydroxide and/or hydrochloric acid.
The plastic container is fabricated from a specially designed multilayer plastic, PL 2501. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period. The suitability of the plastic has been confirmed in tests in animals according to the USP biological tests for plastic containers, as well as by tissue culture toxicity studies.
Last reviewed on RxList: 4/3/2009




Cleocin I.V. Drug Description
Cleocin Phosphate®
(clindamycin) Injection, USP and (clindamycin) Injection in 5% Dextrose
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PHOSPHATE and other antibacterial drugs, CLEOCIN PHOSPHATE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Sterile Solution is for Intramuscular and Intravenous Use
CLEOCIN PHOSPHATE in the ADD-Vantage™ Vial is For Intravenous Use
Only

WARNING
Clostridium difficile associated diarrhea (CDAD) has been reported with
use of nearly all antibacterial agents, including CLEOCIN PHOSPHATE and may
range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial
agents alters the normal flora of the colon leading to overgrowth of C. difficile.
Because CLEOCIN PHOSPHATE therapy has been associated with severe colitis which
may end fatally, it should be reserved for serious infections where less toxic
antimicrobial agents are inappropriate, as described in the INDICATIONS
section. It should not be used in patients with nonbacterial infections such
as most upper respiratory tract infections. C. difficile produces toxins
A and B which contribute to the development of CDAD. Hypertoxin producing strains
of C. difficile cause increased morbidity and mortality, as these infections
can be refractory to antimicrobial therapy and may require colectomy. CDAD must
be considered in all patients who present with diarrhea following antibiotic
use. Careful medical history is necessary since CDAD has been reported to occur
over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against
C. difficile may need to be discontinued. Appropriate fluid and electrolyte
management, protein supplementation, antibiotic treatment of C. difficile,
and surgical evaluation should be instituted as clinically indicated.

DRUG DESCRIPTION
CLEOCIN PHOSPHATE Sterile Solution in vials contains clindamycin phosphate, a water soluble ester of clindamycin and phosphoric acid. Each mL contains the equivalent of 150 mg clindamycin, 0.5 mg disodium edetate and 9.45 mg benzyl alcohol added as preservative in each mL. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.
The chemical name of clindamycin phosphate is L-threo-α-D-galacto-Octopyranoside,
methyl 7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]
amino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-.
The molecular formula is C18H34CIN208PS
and the molecular weight is 504.96.
The structural formula is represented below:








CLEOCIN PHOSPHATE in the ADD-Vantage Vial is intended for intravenous use
only after further dilution with appropriate volume of ADD-Vantage diluent base
solution.
CLEOCIN PHOSPHATE IV Solution in the Galaxy® plastic container for intravenous use is composed of clindamycin phosphate equivalent to 300, 600 and 900 mg of clindamycin premixed with 5% dextrose as a sterile solution. Disodium edetate has been added at a concentration of 0.04 mg/mL. The pH has been adjusted with sodium hydroxide and/or hydrochloric acid.
The plastic container is fabricated from a specially designed multilayer plastic, PL 2501. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period. The suitability of the plastic has been confirmed in tests in animals according to the USP biological tests for plastic containers, as well as by tissue culture toxicity studies.
Last reviewed on RxList: 4/3/2009




Cleocin I.V. Drug Description
Cleocin Phosphate®
(clindamycin) Injection, USP and (clindamycin) Injection in 5% Dextrose
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PHOSPHATE and other antibacterial drugs, CLEOCIN PHOSPHATE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Sterile Solution is for Intramuscular and Intravenous Use
CLEOCIN PHOSPHATE in the ADD-Vantage™ Vial is For Intravenous Use
Only

WARNING
Clostridium difficile associated diarrhea (CDAD) has been reported with
use of nearly all antibacterial agents, including CLEOCIN PHOSPHATE and may
range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial
agents alters the normal flora of the colon leading to overgrowth of C. difficile.
Because CLEOCIN PHOSPHATE therapy has been associated with severe colitis which
may end fatally, it should be reserved for serious infections where less toxic
antimicrobial agents are inappropriate, as described in the INDICATIONS
section. It should not be used in patients with nonbacterial infections such
as most upper respiratory tract infections. C. difficile produces toxins
A and B which contribute to the development of CDAD. Hypertoxin producing strains
of C. difficile cause increased morbidity and mortality, as these infections
can be refractory to antimicrobial therapy and may require colectomy. CDAD must
be considered in all patients who present with diarrhea following antibiotic
use. Careful medical history is necessary since CDAD has been reported to occur
over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against
C. difficile may need to be discontinued. Appropriate fluid and electrolyte
management, protein supplementation, antibiotic treatment of C. difficile,
and surgical evaluation should be instituted as clinically indicated.

DRUG DESCRIPTION
CLEOCIN PHOSPHATE Sterile Solution in vials contains clindamycin phosphate, a water soluble ester of clindamycin and phosphoric acid. Each mL contains the equivalent of 150 mg clindamycin, 0.5 mg disodium edetate and 9.45 mg benzyl alcohol added as preservative in each mL. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.
The chemical name of clindamycin phosphate is L-threo-α-D-galacto-Octopyranoside,
methyl 7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]
amino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-.
The molecular formula is C18H34CIN208PS
and the molecular weight is 504.96.
The structural formula is represented below:








CLEOCIN PHOSPHATE in the ADD-Vantage Vial is intended for intravenous use
only after further dilution with appropriate volume of ADD-Vantage diluent base
solution.
CLEOCIN PHOSPHATE IV Solution in the Galaxy® plastic container for intravenous use is composed of clindamycin phosphate equivalent to 300, 600 and 900 mg of clindamycin premixed with 5% dextrose as a sterile solution. Disodium edetate has been added at a concentration of 0.04 mg/mL. The pH has been adjusted with sodium hydroxide and/or hydrochloric acid.
The plastic container is fabricated from a specially designed multilayer plastic, PL 2501. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period. The suitability of the plastic has been confirmed in tests in animals according to the USP biological tests for plastic containers, as well as by tissue culture toxicity studies.
Last reviewed on RxList: 4/3/2009





Other reviews about Cleocin I.V. on wordpress

Not all posts are fun ones...
  by Trixie
I still feel as though the past few days have been some type of dream. On Saturday, I noticed that Tara had what looked like a small insect […]


Photo Quiz: Unusual lumps to the lower leg with fat atrophy of the ankle
  by FAOJ Editors
Al Kline, DPM , Cathleen Cole-Perez, MD, Christine L. Cantebury, MD ISSN 1941-6806 doi: 10.3827/faoj.2008.0104.0004 Case History A 51 year old female presents with “groin pain”. On initial presentation, the patient had […]


Cleocin no prescription
  by yorkeben
Cleocin no prescription Click Here: Cleocin no prescription China had 196 pharmaceutical medical or legal advice and cleocin no prescription solely, provided for educational and […]


It would be five thousand dollars
  by ktaynegvap
Why, how did you know all that? Doubtlessly Yakaga was saving for him more refined tortures, more exquisite nerve racking. In any case, about twentyfour hundred years ago, […]


There wouldnt be any satis
  by tizxnniratjux
They entered the hall, dressed in cloth of gold and silver, richly embroidered, and adorned with precious stones of great value. Since you have been gone he has […]


Laurel realized she coul
  by dlbluqerki


Its a mistake, Ollie added.
  by aebyixvfmjw
But although she would gladly have given him her hand and thanked him for what he had said at their last meeting, it was always a relief to […]


Dont vanish before I get back.
  by dwzgrhwnnrwrxkn
Today Mary Standish was ahead of him at the table. Standing at the edge of the trench, they realized that they had never both gone down together. Well, […]


Baker, watching Spacehunter on the
  by mzmihlbmvuoclaf
They called them foolcards, and people used to send them to each other. and again he was haunted by hopes. Some of the things are excellent, she […]


So sudden and so fierce was the attack
  by dzuiojwohnrpx
Thats a dear two penoth, chimed in a commonlooking man on the seat behind. There is something damned odd about the whole thing, Lincoln Werth said. In one […]



Other reviews about Cleocin I.V. on web:

Learn about the prescription medication Cleocin I.V. (Clindamycin), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Cleocin I.V. (Clindamycin) Drug Information: Uses, Side Effects ...


Find patient medical information for Cleocin IV on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Cleocin IV : Uses, Side Effects, Interactions, Pictures, Warnings ...


Cleocin side effects, dosage, and drug interactions. All accurate, up-to-date information is written for the consumer by healthcare professionals. Cleocin IV Uses and How to Use


Because CLEOCIN HCL therapy has been associated with severe colitis which may end fatally ... volume of distribution, and area under the serum concentration-time curve) after IV ... Cleocin (Clindamycin) Drug Information: Uses, Side Effects, Drug ...


Cleocin side effects, dosage, and drug interactions. All accurate, up-to-date information is written for the consumer by healthcare professionals. Cleocin IV Dosage and Storage


CLEOCIN PHOSPHATE IV Solution in Galaxy plastic containers is a sterile solution of clindamycin phosphate with 5% dextrose. The single dose Galaxy plastic containers are available as ... Cleocin Phosphate® (clindamycin injection, USP) and (clindamycin ...


Premixed Cleocin Phosphate IV Solution is for intravenous administration using sterile equipment. Check for minute leaks prior to use by squeezing bag firmly. Cleocin Phosphate Official FDA information, side effects and uses.


Learn about Cleocin IV - its uses, dosage, side effects, drug interactions, and safety information on RxList. Cleocin IV Drug information on Uses, Side Effects, Interactions ...


Clindamycin - Cleocin ® The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for ... Clindamycin - Cleocin ® - Intravenous (IV) Dilution


Accurate, FDA approved Cleocin information for healthcare professionals and patients ... volume of distribution, and area under the serum concentration-time curve) after IV ... Cleocin Official FDA information, side effects and uses.





Featured Reviews

Reviews Penetrex

Penetrex Drug Description DRUG DESCRIPTION What are the possible side effects of enoxacin (Penetrex)? If you experience any of the following serious side effects, stop taking enoxacin and seek emergency medical attention or contact...
Read More  |  Review This
Reviews Oxycodone HCl and Ibuprofen

Combunox Drug Description Combunox™ (oxycodone HCl and ibuprofen) Tablets Cardiovascular Risk NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which...
Read More  |  Review This
Reviews Potassium Chloride

Klor-Con Drug Description KLOR-CON® (potassium chloride) Extended-release Tablets, USP., 8 mEq and 10 mEq DRUG DESCRIPTION What are the possible side effects of potassium chloride? Get emergency medical help if you have any...
Read More  |  Review This
Reviews Vicodin

Vicodin Drug Description VICODIN® (hydrocodone bitartrate and acetaminophen) Tablets, USP 5 mg/500 mg DRUG DESCRIPTION What are the possible side effects of acetaminophen and hydrocodone? Get emergency medical help if...
Read More  |  Review This
Reviews Cefzil

Cefzil Drug Description Cefzil® Tablets (cefprozil) 250 mg and 500 mg Cefzil® for Oral Suspension (cefprozil) 125 mg/5 mL and 250 mg/5 mL To reduce the development of drug-resistant bacteria and maintain the effectiveness...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....